Basic Information
Reblozyl
Regulatory Information
EMEA/H/C/004444
June 25, 2020
April 30, 2020
9
October 9, 2024
Company Information
Ireland
Plaza 254 Blanchardstown Corporate Park 2 Dublin 15 D15 T867
Bristol-Myers Squibb Pharma EEIG
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS). Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia. Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS). Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia.
Overview Summary
Reblozyl is a medicine used to treat anaemia (low levels of red blood cells) in adults with the following blood disorders: - myelodysplastic syndromes, a group of conditions where too few blood cells are produced by the bone marrow. Reblozyl is used in patients who need regular blood transfusions and who have a very low to moderate risk of their condition developing into acute myeloid leukaemia (a blood cancer); - beta thalassaemia, a genetic condition in which patients cannot make enough beta globin, a component of haemoglobin (the protein in red blood cells that carries oxygen around the body). These diseases are rare, and Reblozyl was designated an ‘orphan medicine’ (a medicine used in rare diseases). Further information on the orphan designations can be found on ( [myelodysplastic syndromes](/en/medicines/human/orphan-designations/eu-3-14-1331): 22 August 2014; [beta thalassaemia](https://data.ec.europa.eu/ewp/media/f8bd6c6d-3535-49cd-999e-3cc2b4755999): 29 July 2014). The medicine contains the active substance luspatercept.